Le Lézard
Classified in: Health, Business
Subject: LIC

Hylant Announces Exclusive Partnership With Regenexx to Reduce Orthopedic Surgical Spend for Employers


TOLEDO, Ohio, March 12, 2020 /PRNewswire/ -- Hylant, one of the largest privately held insurance brokers in the U.S., has partnered with Regenexx, a network of leading interventional orthopedics clinics. The partnership allows Hylant to offer its clients Regenexx procedures, giving employees access to non-surgical treatments that replace 70% of what was previously only treated with surgery.*

"Treatment of musculoskeletal conditions is one of the largest and fastest growing areas of healthcare spend for our clients and, with the aging of the U.S. population, these costs are becoming a greater burden every year," said Hylant president of Employee Benefits, Lisa Hawker. "I am excited to provide our valued employer groups a high quality, clinically valid alternative to invasive orthopedic surgery."

Regenexx procedures involve precise injections of custom orthobiologics to treat approximately 40 orthopedic conditions. This interventional approach can help employers reduce the cost of individual procedures by up to 70%, while reducing absenteeism and increasing employee satisfaction, all while decreasing the number of unnecessary orthopedic surgeries performed annually.

"In keeping with our rich history of innovative benefit plan designs, Hylant is now able to present our clients and self-funded employers with this unique option in care that's changing the healthcare landscape for employers and patients alike," said Hylant CEO, Mike Hylant.

"Regenexx is looking forward to expanding our mission of producing the best possible patient outcomes for Hylant and their clients through our innovative alternative to orthopedic surgery," said Regenexx CEO Jason Hellickson. "Overuse and misuse of orthopedic surgery is prevalent in our healthcare system today. Our patented regenerative approach to treating common orthopedic conditions is transforming the care pathway of an orthopedic patient who can now avoid a surgical encounter with less risk and less downtime."

Watch a short video about Regenexx here.

Hylant was founded in 1935 and has 16 offices in Ohio, Michigan, Illinois, Indiana, Tennessee, Florida and Georgia. As a member of the Worldwide Broker Network, Hylant offers complete risk management services, employee benefits brokerage and consultation, loss control, healthcare management and insurance solutions for businesses and individuals locally, nationally and internationally.

Contact:

Bridget Scott


Director of Strategic Communications


[email protected]


(317) 817-5142

Regenexx is a nationwide network of physicians who practice Interventional Orthopedics, a new specialty that focuses on using the most advanced regenerative protocols available as an alternative to many orthopedic surgeries. Our procedures use your body's own cells including blood platelets and bone marrow concentrate to treat damaged bone, muscle, cartilage, tendons and ligaments. Regenexx believes in educating patients, offering options and encouraging people to take an active role in their own treatment.

For questions, a quote or inquiries on how to add the Regenexx program to your self-funded health plan or workers' compensation program contact: Regenexx Corporate, [email protected], (877) 341-5968

*This applies only to elective orthopedic surgery without fracture related care and acute care trauma.

SOURCE Regenexx


These press releases may also interest you

at 06:08
The Annual General Meeting of Bioretec Ltd was held on 26 April 2024 in Tampere, Finland. The Annual General Meeting approved the financial statements for the financial year 1 January?31 December 2023 and resolved to discharge the members of the...

at 06:00
IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on April 25, 2024, the Compensation Committee of IDEAYA's Board of Directors granted...

at 06:00
-- Diluted EPS of $2.16; Adjusted Diluted EPS of $2.26 ---- Increases 2024 Full Year Guidance -- 2024 adjusted diluted EPS of $2.26, up over 7% from $2.11 in the first quarter of 2023.Increases 2024 full year adjusted diluted EPS guidance by $0.10 to...

at 06:00
Avantor, Inc. , a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its first...

at 05:12
Swedish Orphan Biovitrum AB (publ) (Sobi®) has established a medium term note programme with a framework amount of SEK 10 billion or the equivalent thereof in EUR (the "MTN Programme"). For this purpose, Sobi has prepared a base prospectus, which...

at 04:00
OMRON Healthcare Co., Ltd. based in Muko, Kyoto Prefecture, Japan, announces to be the official sponsor of May Measurement Month (MMM,) a global campaign to raise awareness of blood pressure screening and promote hypertension prevention, detection,...



News published on and distributed by: